Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis (BMC Nephrology, (2021), 22, 1, (5), 10.1186/s12882-020-02190-0)

  1. Gäckler, A.
  2. Schönermarck, U.
  3. Dobronravov, V.
  4. La Manna, G.
  5. Denker, A.
  6. Liu, P.
  7. Vinogradova, M.
  8. Yoon, S.-S.
  9. Praga, M.
Revista:
BMC Nephrology

ISSN: 1471-2369

Año de publicación: 2021

Volumen: 22

Número: 1

Tipo: Errata

DOI: 10.1186/S12882-021-02242-Z GOOGLE SCHOLAR lock_openAcceso abierto editor
Fuente de los datos: Scopus